Treatment of Madhumeha janya upadrava w.s.r to Diabetic polyneuropathy by Asvagandhadi capsule

Role of Asvagandhadi Capsules in the management of Madhumehajanya upadrava W.S.R.to Diabetic polyneuropathy-An open label randomized controlled clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011154

Enrollment

Registered

2018-01-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetic Polyneuropathy

Interventions

Intervention1: Asvagandhadi Capsule: Asvagandhadi Capsule will be given in Diabetic Polyneuropathy patients in dose of 2 Capsules (Each 500mg) thrice a day with plain water after food for 8 weeks. Con

Eligibility

Inclusion criteria

Inclusion criteria: 1 Fasting plasma glucose >= 126 mg/dl or PostPrandial glucose level >= 200 mg/dl 2 Metabolically stable Type 2 Diabetics with symptomatic diabetic Sensorimotor Polyneuropathy

Exclusion criteria

Exclusion criteria: 1 Age less than 18 years and more than 70 years 2 Patients with complications- Diabetic Nephropathy Diabetic Keto acidosis & Diabetic coma 3 Patients with uncontrolled diabetes 4 Patients with other metabolic & endocrine disorders 5 Patients suffering from HIV TB 6 Patients having any other malignancies any other serious illnesses

Design outcomes

Primary

Measure	Time frame
Relieve in the sign and symptom of Diabetic PolyneuropathyTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Prevention from developing Diabetic foot/ulcerTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactTahera R Mudash

IPGT and RA Gujarat Ayurved University Jamnagar

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026